Background: Neurocognitive impairment remains prevalent in HIV-infected (HIV1) individuals despite highly active antiretroviral therapy (HAART). We assessed the impact of HIV, HAART, and aging using structural neuroimaging.
INTRODUCTION
Before the advent of highly active antiretroviral therapy (HAART), the life expectancy of HIV-infected (HIV1) participants was less than 10 years after initial diagnosis. 1 The introduction of HAART has prolonged the lives of HIV1 participants with many living for more than 20 years after seroconversion. As a result, more HIV1 individuals are reaching advanced ages. 2 If the current trends continue, more than 50% of all HIV1 participants in the United States will be more than 50 years old by 2015. 3 Older HIV1 participants may be at increased risk for accelerated body aging. [4] [5] [6] [7] Similar changes could occur in the brain. [8] [9] [10] Given the importance of brain function to overall clinical outcomes and HAART compliance, it is critical that sensitive indicators of possible brain disruption are discovered.
Brain volumetric measures may represent a robust method for quantifying brain integrity in the presence of HIV. 11 Brain atrophy has been well described since the early discovery of the virus. Many pre-HAART studies demonstrated HIV associated losses within subcortical regions. [12] [13] [14] [15] The degree of atrophy due to HIV has been shown to correlate with poorer neuropsychological performance. [16] [17] [18] [19] Despite the introduction of HAART, changes in brain structure have persisted within impaired and cognitively normal HIV1 individuals. 17, [20] [21] [22] [23] More recent studies in the HAART era have demonstrated that HIV associated brain atrophy occurs not only within subcortical areas but also cortical regions. 17, 21, 24, 25 However, most of the studies have primarily focused on HIV1 participants on stable therapy (approximately 80% of any cohort) 10, 17, [20] [21] [22] [23] [24] [25] rather than HIV1 participants naive to medications.
Historically, brain atrophy within HIV1 patients has been attributed to direct or indirect effects of the virus; yet, growing concerns exist over possible neurotoxic risks associated with long-term administration of HAART. 26, 27 Cell culture studies have demonstrated neuronal loss after the introduction of HAART. 28, 29 In humans, neuropsychological performance improved in a large cohort of HIV1 participants after discontinuing HAART 30 or after participating in a drug holiday. 31 In AU3 particular, efavirenz may be neurotoxic as a higher prevalence of HAND has been observed in HIV1 individuals taking this medication. 32 A recent neuroimaging study has also demonstrated a reduction in neuronal function in HIV1 participants after initiating HAART. 33 These findings suggest a need to further investigate the potential side effects of HAART on brain structure.
Given the continued prevalence of HAND despite HAART, isolating additional factors that might influence brain integrity will be crucial for determining if and when neuroprotective interventions should be administered. The aim of this study was to determine the effects of HIV, HAART, and aging on subcortical and cortical brain volumetric measures. We hypothesized that HIV, and to a lesser extent HAART, is associated with structural atrophy. We additionally predicted that HIV and aging would each independently relate to reductions in brain volumetric measures. Results from the study could support the use of structural neuroimaging as a possible tool for differentiating the impact of HIV from other factors associated with loss of brain integrity.
MATERIALS AND METHODS

Participants and Laboratory Testing
Seventy-eight participants provided written consent approved by the institutional review board at Washington University in St Louis. Individuals with a history of confounding neurological disorders including epilepsy, stroke, and head injury resulting in a loss of consciousness of more than 30 minutes; major psychiatric disorders; or active substance abuse were excluded. Serological status of all HIV1 participants was confirmed by documented positive HIV enzyme-linked immunoassay and Western blot or detection of plasma HIV RNA by polymerase chain reaction. All HIV1 participants had laboratory evaluations [plasma CD4 cell count and HIV viral load (VL)]. The cohort was divided into 3 groups: HIV2 subjects (n = 26), HIV1 individuals on a stable HAART regimen for at least 3 months before imaging (HIV1/ HAART1; n = 26), and HIV1 participants naive to HAART (HIV1/HAART2; n = 26). In addition, a subgroup of the HIV1/HAART2 (n = 12) were longitudinally assessed immediately before starting medications and approximately 6 months after being on a stable therapy (see 
Neuropsychological Evaluation
A AU4 standard neuropsychological performance battery [including Trail-Making Tests A and B, the Hopkins Verbal Learning Test-Revised, and the Digit-Symbol Modalities Test (WAIS-IIIR)] was administered to participants. These tests examine memory, psychomotor speed, and executive function and have been previously used to briefly assess HIV2 associated neurocognitive disorder. 31, 34 Raw scores from each test were standardized using demographic (age, gender, race, education) adjusted normative means. 35 A standardized z score was calculated by subtracting the appropriate normative mean from the raw score and then dividing by the normative standard deviation. A composite neuropsychological summary Z score (NPZ-4) was calculated by averaging z scores from each test. For longitudinal assessments, alternate forms of the Hopkins Verbal Learning Test-Revised were administered. These different versions ensured that subjects were not influenced by previous exposure.
Medications
The specific regimens that HIV1/HAART1 participants (n = 26) received included 14 nucleoside reverse transcriptase inhibitors (NRTIs) 1 non-NRTIs, 11 NRTIs1 protease inhibitors, or 1 NRTIs only. The longitudinal subgroup of HIV1 participants (n = 12) were followed-up before and after receiving either 7 NRTIs 1 non-NRTIs or 5 NRTIs1 protease inhibitors. The ability of a particular antiretroviral (ARV) medication to penetrate across the bloodbrain barrier has been classified using a central penetration effectiveness (CPE) score. 36 The score for each ARV in a HIV1 participant's regimen was summed and a total CPE was calculated for a particular regimen.
Imaging
Scanning was performed using a 3T Siemens Tim TRIO whole-body magnetic resonance scanner (Siemens AG, Erlangen, Germany) with a product transmit/receive head coil. Structural imaging were acquired using a T1-weighted 3-dimensional magnetization-prepared rapid acquisition gradient echo sequence [time of repetition (TR)/echo time (TE)/ inversion time (TI)] = 2400/3.16/1000/milliseconds, flip angle = 8 degrees, 162 slices, and voxel size = 1 · 1 · 1 mm 3 ). Images were visually inspected at the scanner with an additional scan performed if significant movement was observed.
A general automated processing stream was performed using a previously described software package (Freesurfer Version 4.5 (2008) developed at the Martinos Center, Harvard University, Boston, MA; http://surfer.nmr.mgh. harvard.edu). 37, 38 Briefly, magnetization-prepared rapid acquisition gradient echo scans were transformed into a format compatible for Freesurfer. Brain segmentation was accomplished with voxel intensity normalization applied to remove magnetic resonance bias. Skull stripping was performed to remove the surrounding tissue. The brain was subsequently registered to a template volume in Talairach space. Based on prior probabilities of voxel identity assigned by the Freesurfer atlas, 39 subcortical and cortical volumes were subsequently delineated. 38 The quality of segmentation was independently confirmed by 2 reviewers extensively trained in Freesurfer processing (M.O. and J.H.). Segmented volumes were manually edited only when outliers were identified. Once corrected, these scans were reanalyzed. 40 Using a least squares residual regression model, normalized values were obtained from 6 bilaterally selected regions of interest 41 (ROIs). These ROIs included the amygdala, caudate, thalamus, hippocampus, and putamen (F
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ig. 1). The total corpus callosum value was obtained by summing the posterior, posterior-middle, middle, anteriormiddle, and anterior portions. In addition, total cerebral cortex, gray matter, and white matter volumes were determined. For the subgroup that was assessed before and after starting HAART, the longitudinal option of the Freesurfer 4.5 pipeline was used.
Statistical Analysis Cross-sectional Analysis
Brain volumetric values were transformed to the natural logarithmic scale to improve the normality of distribution and to facilitate the interpretation of the results. The differences among groups on the logarithmic scale were then suitably transformed and reported in terms of proportional differences of mean volume among groups. The logarithm transformation allowed for comparisons of relative differences across brain regions. A 1-way analysis of variance was first conducted for each of the brain regions, comparing the 3 groups: HIV2, HIV1/HAART2, and HIV1/HAART1. The P values for the 9 analysis of variances were adjusted for multiple comparisons using the Hochberg algorithm. 42 Volumes that AU1 showed a significant difference at the 0.10 level were considered for further assessment. The exploratory nature of the study justified using this less strict level of selection. In particular, 3 ROIs were subsequently studied. Within these 3 ROIs, a linear model analysis was performed to investigate the difference in the log volumes between groups. These analyses were adjusted for age and/or sex and if these variables were significant at P , 0.20. Among the HIV1 subjects (HIV1/HAART2 and HIV1/ HAART1), the association between laboratory values (current CD4 cell count, nadir CD4 cell count, log 10 plasma HIV VL) and brain volumetric measures were assessed via simple linear regression models. However, for duration of infection, we also controlled for age to detect any effects of HIV infection in addition to natural aging.
Longitudinal Analysis
In a subgroup of HIV1/HAART2 participants, structural imaging was performed immediately before starting medications and at approximately 6 months after the subject FIGURE 1. Using Freesurfer, the corpus callosum, amygdala, caudate, thalamus, and putamen were determined for each subject. *P value for brain regions that were significantly different after a 1-way analysis of variance (correcting for multiple comparisons). All error bars are presented as quartiles.
was successfully on a stable ARV regimen. Brain volumetric measures for each of the above ROIs, laboratory values, and NPZ-4 scores were compared for the 2 time points using simple paired t tests. In addition to main effects of HIV and age, an interaction between HIV and age on brain volume was included if significant at the 0.05 level.
Effects of Age
For the caudate where both age and HIV effects were observed, an exploratory analysis was performed investigating the hypothesis that the HIV effect develops gradually, from no effect at the time of infection, to a steady-state effect, after a certain period of time. In this scenario, the effect of HIV infection on the brain region acts in 2 stages: stage 1 is a transition stage, in which brain loss is gradual, from the uninfected levels to the long-term infected volumes. Stage 2 is the steady-state situation, in which the effect of HIV translates into a constant reduction in brain volume. At this stage, the impact of HIV is in addition to the natural aging process. To this end, we used cross-sectional data using selfreported duration of infection (di). The HIV2 group was included with di = 0, that is, as a surrogate for subjects just before infection. This is a natural exploratory hypothesis and model because it is hard to conceive that the difference in brain volumes between the HIV1 and HIV2 subjects would occur immediately. For additional clarity, we included a smooth estimation of brain volumes. Accordingly, first, a nonparametric lowess smoother 43 was used to explore the effect of time since infection on brain volumes for HIV1 subjects only. Second, the HIV effect was estimated using a "broken-stick" (or piecewise linear) regression model, 44 in which the transition stage between time 0 and T has a linear effect on the log-brain volume, and the steady state, from T onwards, where the effect of HIV infection is constant. T was the time required for the brain volume at seroconversion to transition to the level of a chronic HIV infection. For this analysis, the effect of self-reported duration of infection (D) on the log volume was equal to 0 if D = 0 (ie, for HIV2 subjects), bD if 0 , D , T, and bT if D $ T. As a consequence, bT was the age-adjusted difference in mean response between the HIV2 and the chronically infected HIV1 group. The coefficient b was determined from the regression model. The breakpoint T, representing self-reported duration of transition time associated with atrophy due to HIV, was determined through a grid search that used a maximum likelihood. A 95% confidence interval for T was calculated via parametric bootstrap. To determine the line of best fit, a more gradual change in brain volume was compared with abrupt brain atrophy by the Akaike information criterion. 45 All analyses were performed using R statistical software (version 2.10.1, R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
HIV1 Participants Performed Worse on Neuropsychological Performance Testing than HIV2
Cross-sectional demographic variables for the 3 groups (HIV2, HIV1/HAART2, and HIV1/HAART1) are shown in T T1 able 1. No significant differences were noted among the groups with regard to age, sex, or education. In general, the HIV1 subjects performed poorly on neuropsychological performance testing compared with HIV2 subjects (P = 0.02). This difference was primarily driven by the HIV1/HAART2 group who had worse NPZ-4 scores than HIV2 (P = 0.03) but who were not different from the HIV1/HAART1 (P = 0.09). Differences between HIV1/HAART1 and HIV1/HAART2 included self-reported duration of disease with HIV1/ HAART1 participants infected for a significantly longer time period. The 2 HIV1 groups also differed on HIV markers (CD4 nadir, CD4 current, and log 10 plasma HIV VL). The HIV1/HAART1 subjects had a significantly lower nadir and a higher current CD4 cell count. Log 10 plasma HIV VL was significantly lower in HIV1/HAART1 group with more than 3 quarters of these participants having an undetectable value (,50 copies/mL). These results likely reflect successful reconstitution with ARVs. The average CPE score for the HIV1/HAART1 participants was 7 with regimens chosen by health practitioner in conjunction with patient preferences.
Brain Volumes From Select Regions Were Reduced in HIV1 Individuals
Brain volumetric measures were obtained from the ROIs (Fig. 1) . Only 3 ROIs were significantly different (amygdala, corpus callosum, and caudate) among the groups (adjusted P values = 0.016, 0.049, and 0.090, respectively). For the 3 ROIs, HIV1/HAART2 and HIV1/HAART1 participants had significantly smaller volumetric measures compared with who are HIV2. HAART did not affect brain structure as volumetric measures for each of the regions were similar for HIV1/HAART2 and HIV1/HAART1. The total cerebral cortex volume as well as gray and white matter volumes was similar among the groups (see Table, Supplemental Digital Content 2, http://links.lww.com/QAI/A264).
Changes in Brain Volumetrics Did Not Correlate With Typical Laboratory Markers of HIV Disease
For the HIV1 groups, the relationship between known markers of HIV disease and volumetric measures were also assessed. No significant correlations existed between volumetric measures within the 3 ROIs and either current CD4 cell count or CD4 nadir cell count. HIV VL was correlated with caudate volume for HIV1/HAART1 participants (P = 0.001). However, these results were primarily weighted by 6 HIV1/HAART1 participants who had escaped viral suppression (,50 copies/mL) despite being on HAART. If these subjects were removed from the analysis, then no significant differences were seen. In addition, no significant correlations existed between log 10 plasma HIV VL and brain volumetric measures for HIV1/HAART2 subjects. With regard to neuropsychological performance, no significant correlations existed between NPZ-4 scores and volumetric measurements for each of the 3 regions (all P . 0.30).
Brain Volumetric Measures Were Inversely Correlated With Age in HIV1 Participants
A decrease in caudate volume was seen with increasing age for the 3 groups. Because HIV1/HAART2 and HIV1/ HAART1 participants had similar results (data not shown), these 2 groups were combined into a single group (HIV1) and compared with HIV2 subjects (F F2 ig. 2). Both increasing age and HIV infection were each associated with significant decreases in caudate volume, but no significant interaction was present. For every 10 years, HIV led to a 6% decrease in caudate volume, whereas aging resulted in a 4% decrease (T T2 able 2). Overall, for a given age, caudate volumetric values in a HIV1 subject were equivalent to a HIV2 participant who was approximately 17 years older. For the amygdala and the corpus callosum, significant effects of HIV but not aging were observed. No significant age by HIV interactions were seen within these 2 regions (Table 2 ).
HAART Does Not Change Brain Volumetrics
Within the subset of the HIV1/HAART2 that started medications, neuroimaging was performed both before and after starting HAART. The introduction of HAART led to a significant reduction in log 10 plasma HIV VL (P , 0.001) and an increase in CD4 cell count (P = 0.03; data not shown). However, there was no change in volumetric measures within select ROIs (ie, caudate) after starting HAART (see Figure, Supplemental Digital Content 3, http://links.lww.com/QAI/A265). Some improvements on neuropsychological performance testing were seen at the second assessment, but this difference was not statistically significant (P = 0.65). For each of the ROIs, there was no significant effect of self-reported duration of HAART on brain volume (data not shown).
Caudate Volume Atrophies After Approximately 13 Years of HIV Infection
The difference in brain volume between the HIV1 and HIV2 subjects suggests that following the time of selfreported infection, certain regions may be at increased risk for atrophy. Based on an exploratory model that uses the broken-stick method, the estimated time (T) needed for the brain volume to transition from self-reported date of HIV1 infection to HIV2, the level for chronically HIV1 infection was 161 months (13.4 years), 95% confidence interval (3-300 months) (F F3 ig. 3). Although a significant degree of variability was observed, a more gradual decline in brain volume fit the data better than a one implying abrupt atrophy (improvement in Akaike information criterion = 0.57).
DISCUSSION
HIV is associated with a significant reduction in volume within select subcortical regions including the amygdala, caudate, and corpus callosum. A reduction in brain volumetrics was seen for HIV1 participants regardless of the presence or absence of HAART. Observed changes in brain volume due to HIV infection were independent of aging. Our results suggest that HIV1 individuals continue to have volumetric loss even in the HAART era.
Changes in brain volume due to HIV were primarily seen within subcortical areas such as the amygdala, caudate, and corpus callosum. Observed changes correspond with previous volumetric studies that showed significant decreases in particular subcortical regions such as the caudate, amygdala, and hippocampus. 9, 10, 20, 21, 23 Changes have also been previously noted within the corpus callosum using volumetrics. 21, 46 In contrast, other subcortical areas such as the thalamus, putamen, or parahippocampus were not affected. 17, 24, 25 The precise reason why specific subcortical areas are affected remains unknown, but may reflect the close proximity of these structures to the ventricles. 47 This proximity may allow for easier viral penetration by HIV-infected mononuclear cells trafficking into the brain as well as increased HIV toxic products, such as gp120 and Tat. [48] [49] [50] In particular, the highest concentrations of HIV have been observed in the corpus callosum and caudate compared with other brain regions. 20, 48, 51 Our results suggest that pathological changes continue to persist, primarily in subcortical regions, despite HAART.
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In this analysis, we observed no significant differences in total cerebral cortex and gray matter or white matter volume for HIV1 participants compared with who are HIV2. A number of studies have observed a decrease in gray matter because of HIV infection, 17, 20, 24, 52 whereas others also observed no significant changes. 12, [53] [54] [55] [56] Discrepancies between the various studies may be because of differences in the degree of impairment in HIV1 participants as well as the inclusion of matched HIV-participants.
Interestingly within the HIV1 participants, similar volumetric values were observed for HIV1/HAART1 and HIV1/ HAART2 subjects. Furthermore, when assessing HIV1/ HAART2 participants both before and after starting on medications, no significant changes were observed in subcortical and cortical volumes despite good virological control. Although no deleterious structural alterations could be specifically attributed to HAART, this cross-sectional study was not designed to determine with certainty if HAART is toxic to brain structures. Larger longitudinal studies with structured assessment end points are required for HIV1 participants receiving HAART. In this study, we also observed no significant correlations between laboratory values such plasma HIV values (CD4 current, CD4 nadir, or log 10 plasma HIV VL) and structural neuroimaging measures. A number of studies have observed no correlation between current CD4 or nadir CD4 and brain volumes. 12, 22, 25, 57 However, other investigators have observed a strong correlation between laboratory values, especially CD4 nadir, and brain volumes. 17, 21, 46, [53] [54] [55] [56] 58 A complex relationship may exist with a reduction in brain volumetric loss occurring not only at a lower CD4 nadir but also at a higher current CD4 cell count because of significant inflammation associated with reconstitution. 55 Observed differences between various groups may reflect differences (1) in the sample size studied, (2) when a subject was scanned in relation to starting medications, (3) in methods used for brain segmentation, 46 and (4) in regions investigated. Additional longitudinal studies of larger cohorts of HIV1 participants on stable HAART need to be performed.
Our exploratory analysis using a broken stick model demonstrated that brain atrophy may slowly develop over time. Based upon the self-reported duration of infection, our model estimates that a period of approximately 13 years is required for atrophy within the caudate to reach levels observed in this study. These changes can occur despite initiation of HAART because most HIV1 participants were prescribed medications when they met the current guidelines (CD4 cell count ,350 cells/mm 3 or an AIDS-defining illness). A wide variability existed for this effect. Our exploratory results suggest that a chronic subclinical process continues to occur within the caudate despite peripheral control of viral replication. 24 Observed atrophy within the caudate could reflect low-level inflammation and neuronal loss. 10, 21 Initiation of adjunctive therapies soon after initial infection could be beneficial in an attempt to preserve brain integrity within the caudate. 16 Additional longitudinal studies are required in acute and early HIV1 participants to confirm the effects of HIV on this brain structure.
Both HIV and aging independently affect brain volume regardless of HAART status. Previous studies using structural imaging, 24 magnetic resonance spectroscopy, 10, 33 and arterial spin labeling 8 have shown that age and HIV independently affect the brain. Our results are similar to these previous studies. In our cohort, HIV led to approximately 17 years of aging of the brain. No interaction occurred between HIV and aging. However
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, in each of the previous studies that assessed HIV and aging, HIV1 participants both on and off HAART were combined into a single group and compared with HIV2 HIV2. In this study, HIV1 individuals were specifically divided into 2 groups (HIV1/HAART2 and HIV1/HAART1) to identify the possible effects of HAART on structural brain changes as they relate to HIV. No AU6 significant differences were seen between HIV1/ HAART2 and HIV1/HAART2 with regard to caudate volume as a function of age. Overall, our results suggest that a decrease in brain integrity within older HIV1 participants, even those taking HAART, may indicate that these individuals have increased vulnerability for subsequently developing neurodegenerative disorders.
In terms of neuropsychological function, the HIV1/ HAART2 group performed worse than HIV2 group. The HIV1/HAART1 also had mild cognitive disturbances but did not perform significantly worse than HIV2 individuals. These changes in neuropsychological performance were not correlated with volumetric measures. The HIV1/HAART1 group had lower mean volumetric measures for most ROIs despite having better NPZ-4 test performances. The etiology of this discordance between neuroimaging and neuropsychological performance remains unknown. Previously, HAART has been shown to lead to mild improvements in neuropsychological performance. 26 Although a slight improvement in neuropsychological performance was seen after starting HAART, these changes were not significant in the subgroup of HIV1 participants assessed longitudinally. These changes may be influenced by practice effects or the test battery used. A rather limited number of neuropsychological tests were administered in this study and therefore may not be sensitive to the possible subtle changes in cognition. Previous work has described the relationships between neuropsychological performance and neuroimaging in greater detail. 18 A limitation of this study was that the 2 HIV1 groups differed significantly in their self-reported duration of HIV infection. Participants may not have accurate recall of the time they seroconverted or may initially present to a health care provider at different stages of the disease. Larger longitudinal studies that follow-up HIV1 participants soon after documented seroconversion are needed to assess changes in brain volume due to HIV. In addition, this study was unable to assess if particular regimens could further modify brain atrophy. The effects of CPE on brain volumetric measures could not be assessed because most participants were prescribed only a limited number of regimens. On average, most HIV1 participants were taking regimens with relatively good brain penetration (average CPE = 7). Further studies comparing brain volumetric measures between HIV1 participants on high and low CPE regimens are needed.
In summary, this study has demonstrated that HIV continues to be associated with brain atrophy within subcortical regions in the HAART era. It is possible that this volume change occurs slowly over time even with the initiation of HAART. It is therefore important that HIV is diagnosed early with additional neuroprotective agents considered for preventing volume loss with subcortical areas. In addition, both HIV and age could independently decrease brain volume, but no significant interaction was observed. Additional studies of older HIV1 (.50 years old) are needed to determine if they are at increased vulnerability for subsequently developing neurodegenerative diseases.
